a wholly owned subsidiary of La Jolla Pharmaceutical Company

Pipeline Products for Out-Licensing

Our research and discovery initiatives, driven by our proprietary chemical technology, have yielded novel compounds targeting significant bacterial threats. These compounds are now in the clinical trial phase of development and available for out-licensing.

TP-271


  • A fully synthetic tetracycline antibiotic in phase 1 clinical testing
  • Development program targets respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens
  • Potent activity in vitro against Gram-negative and Gram-positive pathogens associated with respiratory tract infections
  • National Institutes of Health’s National Institute of Allergy and Infectious Diseases funded preclinical development and phase 1 study
  • Granted Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration for both IV and oral formulations
  • Positive safety and pharmacokinetic data from IV single-ascending and multiple-ascending dose studies

TP-6076


  • A fully synthetic tetracycline antibiotic in phase 1 clinical development
  • Potent activity in vitro against multidrug-resistant Gram-negative pathogens
  • Phase 1 multiple-ascending dose study complete
  • Received $4 million in funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support development

Please contact us to learn more.

Submit Medical Inquiries
To:

Please enter a valid email address.

From:

Please enter a valid email address.

Share information about Tetraphase

Cancel

Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.

OK